About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
Our Science
  • CC-90002 (Anti-CD47 Antibody)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    CC-90002 is an anti-CD47 antibody. CD47 interacts with signal regulatory protein-α (SIRPα) on macrophages to inhibit cell phagocytosis. It plays an important role in the ability of the immune system to detect nonself from self.1-4 Loss of CD47 expression results in the cell being recognized as foreign for phagocytosis.2,5

     

    MaAb, monoclonal antibody; SIRPα, signal-regulatory protein α.

    CC-90002 by Disease State

    CC-90002 in Lymphoma

    Phase 2
    Non-Hodgkin lymphoma

    View Trials Investigating CC-90002 in Lymphoma
    View Rationale for Clinical Development

    Rationale for Clinical Development

    Evidence suggests that upregulation of CD47 may allow tumor cells to evade phagocytosis, negatively impacting the function of macrophages that could play a major role in recognition and clearance of tumor cells.5 CD47 has been shown to be expressed and upregulated in various hematologic malignancies, including non-Hodgkin lymphoma.1,3 Preclinical studies have shown that inhibiting CD47 enables phagocytosis of non-Hodgkin lymphoma cells in vitro and reduces non-Hodgkin lymphoma burden in mouse models.3,4

    View Related Pathways

    References

    1. Chao MP, et al. Curr Opin Immunol. 2012;24:225-232. PMID: 22310103
    2. Barclay AN, et al. Annu Rev Immunol. 2014;32:25-50. PMID: 24215318
    3. Chao MP, et al. Cell. 2010;142:699-713. PMID: 20813259
    4. Chao MP, et al. Blood. 2011;118:4890-4901. PMID: 21828138
    5. Jaiswal S, et al. Trends Immunol. 2010;31:212-219. PMID: 20452821